The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development
Open accessAbstract
Toxoplasmosis, caused by the apicomplexan parasite Toxoplasma gondii, is one of the most damaging parasite-borne zoonotic diseases of global importance. While approximately one-third of the entire world’s population is estimated to be infected with T. gondii, an effective vaccine for human use remains unavailable. Global efforts in pursuit of developing a T. gondii vaccine have been ongoing for decades, and novel innovative approaches have been introduced to aid this process. A wide array of vaccination strategies have been conducted to date including, but not limited to, nucleic acids, protein subunits, attenuated vaccines, and nanoparticles, which have been assessed in rodents with promising results. Yet, translation of these in vivo results into clinical studies remains a major obstacle that needs to be overcome. In this review, we will aim to summarize the current advances in T. gondii vaccine strategies and address the challenges hindering vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there is no safe and effective vaccine for T. gondii (Chu and Quan, 2021).”
From A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice (2023) · cites this paper as Chu and Quan, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Howe, D. K., & Sibley, L. D. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.6.1561 · Cited by 1,465
Carbohydrate vaccines: developing sweet solutions to sticky situations?
Astronomo, R. D., & Burton, D. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3012 · Cited by 629
Kushnir, N., Streatfield, S. J., & Yusibov, V. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 610
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00057-17 · Cited by 558
Toxoplasmosis in sheep—The last 20 years
Dubey, J. P. (2009) · Veterinary Parasitology · doi:10.1016/j.vetpar.2009.02.026 · Cited by 514
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Halonen, S. K., & Weiss, L. M. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53490-3.00008-x · Cited by 380
Recent Advances in Subunit Vaccine Carriers
Vartak, A., & Sucheck, S. J. (2016) · Vaccines · doi:10.3390/vaccines4020012 · Cited by 325
Elbez, A., Ajzenberg, D., Dardé, M., Cohen, R., Dumètre, A., Yera, H., Gondon, E., Janaud, J., & Thulliez, P. (2008) · The Journal of Infectious Diseases · doi:10.1086/595793 · Cited by 321
Vaccination: the cornerstone of an efficient healthcare system
Rémy, V., Zöllner, Y. F., & Heckmann, U. (2015) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v3.27041 · Cited by 257
Cited by
Sorted by citations
The pathogenicity and virulence of Toxoplasma gondii
Sanchez, S. G., & Besteiro, S. (2021) · Virulence · doi:10.1080/21505594.2021.2012346 · Cited by 151
Toxoplasmosis vaccines: what we have and where to go?
Zhang, Y., Li, D., Lu, S., & Zheng, B. (2022) · npj Vaccines · doi:10.1038/s41541-022-00563-0 · Cited by 77
Advances and Challenges in Diagnostics of Toxoplasmosis in HIV-Infected Patients
Wesołowski, R., Pawłowska, M., Smoguła, M., & Szewczyk‐Golec, K. (2023) · Pathogens · doi:10.3390/pathogens12010110 · Cited by 50
A Comprehensive Review of Toxoplasmosis: Serious Threat to Human Health
Khairullah, A. R., Kurniawan, S. C., Widodo, A., Effendi, M. H., Hasib, A., Silaen, O. S. M., Ramandinianto, S. C., Moses, I. B., Riwu, K. H. P., Yanestria, S. M., et al. (2024) · The Open Public Health Journal · doi:10.2174/0118749445281387240202094637 · Cited by 49
Review of Toxoplasmosis: What We Still Need to Do
Farhab, M., Aziz, M. W., Shaukat, A., Cao, M.-X., Hou, Z., Huang, S., Li, L., & Yuan, Y. (2025) · Veterinary Sciences · doi:10.3390/vetsci12080772 · Cited by 39
Metadata
- Authors
- Chu, K.-B., & Quan, F.-S.
- Affiliations
- Kyung Hee University (KR)
- Corresponding author
- Quan, Fu-Shi
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-04-21
- Volume
- 9
- Issue
- 5
- Pages
- 413
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC8143161
- OpenAlex
- W3152765551
- Cited by
- 92
- References
- 118
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 19 · 2023: 15 · 2022: 13 · 2021: 7
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF) (2018R1A6A1A03025124)
- Ministry of Health & Welfare, Republic of Korea (HV20C0085, HV20C0142)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Coccidia and coccidiosis research
- Life Sciences › Immunology and Microbiology › Parasitology › Parasitic infections in humans and animals
- Keywords
- Toxoplasma gondii, toxoplasmosis, vaccine development, zoonotic parasitic disease, nucleic acid vaccines, subunit vaccine, live attenuated vaccine, nanoparticle vaccine, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development. https://app.cochat.ai/papers/10.3390/vaccines9050413
- The paper
- Chu, K.-B., & Quan, F.-S. (2021). Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development. Vaccines. https://doi.org/10.3390/vaccines9050413
